ILLUMINA INC

ILMNNASDAQ

🏆 #363 by market capEarnings Oct 28 · PostUS Equity

$192.84▲ $1.06 (+0.55%)

🌙 After hours$192.84▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.6%

7d—

14d—

30d—

1y—

🏦Market Cap

$29.18B

Mid Cap

📈Revenue Growth (YoY)

+4.9%

Slowing

📊Gross Margin

66.4%

High

💵FCF Margin

20.7%

Strong

⚖️P/S Ratio

6.4x

Fair

Otter Score

Weak

No chart data available for ILMN.

Trading Snapshot

Day Range: $189.78 – $195.12
52-Week Range: $88.00 – $207.00
Volume: $5.75B
Avg Volume: $6.95B
Shares Outstanding: 151.3M
Next Earnings: Sep 28, 2026

Fundamentals Snapshot

Annual Revenue: $4.34B
Last Q Revenue: $1.16B
P/E Ratio: 34.9
P/S Ratio: 6.4x
EPS (TTM): $5.38
Dividend Yield: —

Why Investors Own ILMN

✓High-growth profile — revenue up +8.0% YoY with expanding US Equity exposure.
✓Healthy economics — 41% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$4.34B▲ +10.0% YoY

Gross Margin (TTM)

41.1%▲ +3.5% YoY

Operating Income (TTM)

$1.45B▲ +10.0% YoY

Free Cash Flow (TTM)

$1.12B▲ +10.0% YoY

About ILLUMINA INC

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

🦦